Mural Oncology (NASDAQ:MURA) Stock Rating Lowered by Raymond James

Raymond James downgraded shares of Mural Oncology (NASDAQ:MURA) from a strong-buy rating to an outperform rating in a research report report published on Tuesday, MarketBeat.com reports. They currently have $18.00 target price on the stock.

A number of other analysts have also recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Mural Oncology in a research note on Wednesday, March 12th. Jones Trading reiterated a “hold” rating on shares of Mural Oncology in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.00.

Mural Oncology Price Performance

NASDAQ MURA opened at $1.35 on Tuesday. The firm’s fifty day moving average price is $3.77 and its 200 day moving average price is $3.58. Mural Oncology has a 12 month low of $1.28 and a 12 month high of $5.12. The company has a market capitalization of $23.26 million, a price-to-earnings ratio of -0.15 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same quarter in the prior year, the business posted ($3.57) EPS. As a group, sell-side analysts forecast that Mural Oncology will post -7.54 earnings per share for the current year.

Institutional Investors Weigh In On Mural Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of MURA. Commerce Bank purchased a new stake in Mural Oncology during the third quarter worth $39,000. FMR LLC raised its stake in shares of Mural Oncology by 124.7% during the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after buying an additional 11,423 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Mural Oncology during the 4th quarter worth $68,000. Two Sigma Advisers LP purchased a new stake in shares of Mural Oncology in the 4th quarter worth about $84,000. Finally, Bridgeway Capital Management LLC acquired a new stake in Mural Oncology in the 4th quarter valued at about $94,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.